Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 HKD | -1.47% | +4.69% | -8.22% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Evolution of the average Target Price on Ascletis Pharma Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
EPS Revisions
- Stock Market
- Equities
- 1672 Stock
- Consensus Ascletis Pharma Inc.